Dave & Buster’s, American Eagle, Cabaletta, Abeona, Oncolytics Insider Shock

Insiders have been trading these 5 stocks: ((PLAY)), ((AEO)), ((CABA)), ((ABEO)) and ((ONCY)). Here is a breakdown of their recent trades and their value.

SVP and chief legal officer Rodolfo Jr. Rodriguez has signaled confidence in Dave & Buster’s Entertainment by purchasing 730 shares, in a transaction valued at $14,673. While the absolute number of shares may seem modest, insider buying from a senior vice president and CLO often draws attention because it can reflect internal optimism about the company’s near‑term prospects. This $14,673 purchase adds to the narrative that management believes in the underlying fundamentals of Dave & Buster’s business model and its ability to navigate a competitive entertainment and dining landscape.

American Eagle Outfitters has seen notable insider selling activity, headlined by Director Noel Joseph Spiegel and Executive Chairman Jay Schottenstein. Spiegel sold 1,896 shares of American Eagle stock for total proceeds of $48,651, trimming his exposure. Far more striking, Schottenstein sold a massive 1,048,579 shares, a sale worth $26,813,077. Such a large transaction from a key insider can reflect portfolio rebalancing, tax planning, or a view that the current valuation already prices in a great deal of optimism, and investors will be watching closely to see whether these sales are followed by any changes in company guidance or market sentiment.

Cabaletta Bio has attracted a wave of insider buying across its leadership team and board, suggesting broad-based internal conviction. Director Shawn Tomasello acquired 22,725 shares for $50,222, while Director Mark Simon bought 11,061 shares for $25,219 and Director Gwendolyn Binder picked up 11,312 shares for $24,660. At the executive level, President & CEO Steven Nichtberger made a substantial commitment by buying 45,000 shares worth $100,350. Additional purchases came from CMO Chang David J., who bought 8,800 shares for $19,888, GC Gerard Michael, who acquired 6,600 shares for $14,916, and CCO Steve Gavel, who bought 22,170 shares for $50,104. This broad insider buying across multiple roles, totaling well over 100,000 shares and several hundred thousand dollars, underscores a strong internal belief in Cabaletta Bio’s pipeline and future.

In contrast, Abeona Therapeutics has experienced a coordinated wave of insider selling by several members of its leadership and board. Director Mark Alvino sold 13,500 shares for $70,470, while Director Joseph Walter Vazzano disposed of 18,666 shares for $99,489. Adding to the selling pressure, SVP and CLO Brendan M. O’Malley sold 13,578 shares worth $72,370. The largest transaction came from CEO Vishwas Seshadri, who sold 69,832 shares of Abeona Therapeutics stock, generating proceeds of $372,204. Collectively, these sales represent a significant amount of insider supply hitting the market, and investors may weigh these moves against recent stock performance and clinical or regulatory milestones.

Oncolytics Biotech stands out with a single, but substantial, insider purchase that may capture investor attention. Director Bernd R. Seizinger acquired 100,000 shares of Oncolytics Biotech stock in one transaction valued at $103,000. This six‑figure commitment from a board member can be interpreted as a vote of confidence in the company’s oncology pipeline and long‑term prospects. With 100,000 shares added to his holdings, Seizinger’s purchase may signal that internal stakeholders see meaningful upside potential relative to Oncolytics Biotech’s current market valuation, especially as it progresses through critical stages of clinical development.